Artery Therapeutics, Inc.
Publicly observedSan Ramon, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Ramon | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Artery Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JHVKQN55S7Y5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK
USD 2,267,403.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant10 Sept 2025Publicly observed
NIH SBIR/STTR award: Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys
USD 2,454,521.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.